Brief: Entera Bio Announces Successful EB613 End-Of-Phase 2 Meeting With FDA: FDA Agrees To Phase 3 12-Month Study With Lumbar Spine BMD As Primary Endpoint
04/01/2022 14:38
Jan 4 (Reuters) - Entera Bio Ltd 5DT.F :
* ENTERA BIO ANNOUNCES SUCCESSFUL EB613 END-OF-PHASE 2
MEETING
WITH FDA: FDA AGREES TO PHASE 3 12-MONTH STUDY WITH LUMBAR SPINE
BMD AS PRIMARY ENDPOINT
Source text for Eikon: ID:nGNX2hFnwP
Further company coverage: 5DT.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Entera Bio
See all newsBrief: Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., As Chief Medical Officer Ahead Of Planned Eb613 Phase 3 Initiation
Corrected: Israel's Entera Bio Q2 net loss widens
NASDAQ RESUMED AT 10:02 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:57 AM
Brief: Entera Bio Announces Pricing Of Oversubscribed $275 Million Private Placement